EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influenza Vaccine Effectiveness in Australia During 2017–2019

Tanya Diefenbach-Elstob iD, Monique B Chilver iD, Violeta Spirkoska, Kylie S Carville iD, Clyde Dapat iD, Mark Turra, Thomas Tran, Yi-Mo Deng iD, Heidi Peck iD, Ian G Barr iD, Nigel Stocks iD, Sheena G Sullivan iD

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Tanya Diefenbach-Elstob und 11 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity…. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Department of Health and Aged Care, Victorian Government Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vaccine effectiveness (VE) estimates provide important post‐marketing assessment of how well seasonal influenza vaccines prevent medically attended influenza disease. We present VE estimates for primary care in Australia for the 2017–2019 seasons.

Methods

The study used a test‐negative design. Influenza VE was estimated from adjusted logistic regression models comparing the odds of vaccination among influenza‐test‐positive cases and test‐negative non‐cases. Estimates were made overall and separately by influenza type, subtype, lineage and clade and stratified by age group. Antigenic similarity of influenza viruses to vaccine strains was assessed using the haemagglutination inhibition assay, and phylogenetic analysis was performed on sequenced viruses.

Results

The study included 2879, 1973 and 3371 general practice patients with swabs collected during 2017, 2018 and 2019 respectively. Influenza A(H3N2) was predominant in 2017 and 2019, while influenza A(H1N1)pdm09 predominated in 2018. VE was estimated at 37% (95% CI 22, 48) for the 2017 season, 53% (95% CI 33, 67) for 2018 and 50% (95% CI 40, 58) for 2019. In general, estimates were higher against A(H1N1)pdm09 and influenza B viruses and lower against A(H3N2) viruses. Across the three seasons, antigenic data identified a greater proportion of A(H1N1)pdm09 and influenza B viruses than A(H3N2) viruses as antigenically similar to the cell‐propagated reference viruses. VE estimates by clade generally indicated higher VE among viruses in the same clade as the vaccine viruses.

Conclusions

Influenza VE varied across influenza seasons and by influenza type/subtype. Given the ongoing evolution of circulating influenza viruses, vaccine improvements are needed, especially for influenza A(H3N2).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesVaccine EfficacyHumansAustraliaAdultMiddle AgedAdolescentYoung AdultFemaleMaleInfluenza A Virus, H3N2 SubtypeChild, PreschoolAgedChildInfluenza A Virus, H1N1 SubtypeInfluenza B virusInfantPhylogenyAged, 80 and overSeasonsVaccination

Stichwörter der Autor:innen

case–control studyinfluenzasurveillancetest‐negative designvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Australian Sentinel Practices Research Network (ASPREN), Discipline of General Practice, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
  • Victorian Influenza Sentinel Practices Network (VicSPIN), Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Aus…
  • Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Microbiology and Infectious Diseases, Public Health Laboratory, SA Pathology, Adelaide, South Australia, Australia.
  • Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

ORCID-Profile: Tanya Diefenbach-Elstob, Monique B Chilver, Kylie S Carville, Clyde Dapat, Yi-Mo Deng, Heidi Peck, Ian G Barr, Nigel Stocks, Sheena G Sullivan

Förderung

  • Australian Government Department of Health and Aged Care
  • Victorian Government Department of Health and Human Services

Zitieren

APA

Diefenbach-Elstob, T., Chilver, M. B., Spirkoska, V., Carville, K. S., Dapat, C., Turra, M., Tran, T., Deng, Y. M., Peck, H., Barr, I. G., Stocks, N., & Sullivan, S. G. (2025). Influenza Vaccine Effectiveness in Australia During 2017–2019. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70137

Vancouver

Diefenbach-Elstob T, Chilver MB, Spirkoska V, Carville KS, Dapat C, Turra M, et al. Influenza Vaccine Effectiveness in Australia During 2017–2019. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70137

BibTeX
@article{DiefenbachElstob2025,
  author = {Diefenbach-Elstob, Tanya and Chilver, Monique B and Spirkoska, Violeta and Carville, Kylie S and Dapat, Clyde and Turra, Mark and Tran, Thomas and Deng, Yi-Mo and Peck, Heidi and Barr, Ian G and Stocks, Nigel and Sullivan, Sheena G},
  title = {Influenza Vaccine Effectiveness in Australia During 2017–2019},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70137}
}
Kostenlos starten →